Guardion Health Sciences, Inc. (GHSI)
USD 3.22
(0.0%)
USD 3.22
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 11.91 Million USD | -45.04% |
| 2022 | 21.68 Million USD | -7.56% |
| 2021 | 23.46 Million USD | 137.92% |
| 2020 | 9.86 Million USD | -23.42% |
| 2019 | 12.87 Million USD | 249.81% |
| 2018 | 3.68 Million USD | -50.05% |
| 2017 | 7.37 Million USD | 2712.58% |
| 2016 | 262.04 Thousand USD | 6.62% |
| 2015 | 245.76 Thousand USD | -10.26% |
| 2014 | 273.87 Thousand USD | -40.8% |
| 2013 | 462.64 Thousand USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 10.4 Million USD | -12.68% |
| 2024 Q2 | 15.29 Million USD | 47.01% |
| 2023 Q4 | 11.91 Million USD | -7.45% |
| 2023 Q2 | 13.47 Million USD | -6.55% |
| 2023 FY | 11.91 Million USD | -45.04% |
| 2023 Q3 | 12.87 Million USD | -4.43% |
| 2023 Q1 | 14.41 Million USD | -33.51% |
| 2022 Q2 | 29.83 Million USD | -5.65% |
| 2022 Q1 | 31.62 Million USD | 34.78% |
| 2022 FY | 21.68 Million USD | -7.56% |
| 2022 Q4 | 21.68 Million USD | -23.18% |
| 2022 Q3 | 28.22 Million USD | -5.38% |
| 2021 Q2 | 41.28 Million USD | -7.65% |
| 2021 Q3 | 38.61 Million USD | -6.47% |
| 2021 Q4 | 23.46 Million USD | -39.24% |
| 2021 Q1 | 44.7 Million USD | 353.33% |
| 2021 FY | 23.46 Million USD | 137.92% |
| 2020 Q2 | 14.03 Million USD | -8.17% |
| 2020 Q3 | 12.15 Million USD | -13.36% |
| 2020 Q4 | 9.86 Million USD | -18.9% |
| 2020 Q1 | 15.28 Million USD | 18.69% |
| 2020 FY | 9.86 Million USD | -23.42% |
| 2019 Q3 | 8.95 Million USD | 57.16% |
| 2019 FY | 12.87 Million USD | 249.81% |
| 2019 Q4 | 12.87 Million USD | 43.79% |
| 2019 Q2 | 5.69 Million USD | 43.5% |
| 2019 Q1 | 3.97 Million USD | 7.87% |
| 2018 Q3 | 3.88 Million USD | -20.12% |
| 2018 Q4 | 3.68 Million USD | -5.27% |
| 2018 FY | 3.68 Million USD | -50.05% |
| 2018 Q1 | 5.91 Million USD | -19.73% |
| 2018 Q2 | 4.86 Million USD | -17.77% |
| 2017 Q2 | 512.73 Thousand USD | -20.32% |
| 2017 Q1 | 643.46 Thousand USD | 145.55% |
| 2017 FY | 7.37 Million USD | 2712.58% |
| 2017 Q4 | 7.37 Million USD | 90.04% |
| 2017 Q3 | 3.87 Million USD | 656.4% |
| 2016 Q1 | - USD | -100.0% |
| 2016 FY | 262.04 Thousand USD | 6.62% |
| 2016 Q4 | 262.04 Thousand USD | -56.35% |
| 2016 Q3 | 600.33 Thousand USD | 25.74% |
| 2016 Q2 | 477.42 Thousand USD | 0.0% |
| 2015 Q1 | -1.81 Million USD | -761.84% |
| 2015 Q4 | 245.76 Thousand USD | -15.51% |
| 2015 Q3 | 290.88 Thousand USD | 0.0% |
| 2015 FY | 245.76 Thousand USD | -10.26% |
| 2014 FY | 273.87 Thousand USD | -40.8% |
| 2014 Q4 | 273.87 Thousand USD | 0.0% |
| 2013 FY | 462.64 Thousand USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| ANI Pharmaceuticals, Inc. | 904.42 Million USD | 98.682% |
| Aquestive Therapeutics, Inc. | 57.41 Million USD | 79.243% |
| Collegium Pharmaceutical, Inc. | 1.14 Billion USD | 98.958% |
| Cosmos Health Inc. | 66.29 Million USD | 82.023% |
| Dynavax Technologies Corporation | 997.09 Million USD | 98.805% |
| Intra-Cellular Therapies, Inc. | 728.29 Million USD | 98.364% |
| Pacira BioSciences, Inc. | 1.57 Billion USD | 99.243% |
| Sunshine Biopharma, Inc. | 27.34 Million USD | 56.419% |
| Sunshine Biopharma, Inc. | 27.34 Million USD | 56.419% |
| SCYNEXIS, Inc. | 128.41 Million USD | 90.719% |
| Safety Shot Inc | 12.7 Million USD | 6.224% |
| China SXT Pharmaceuticals, Inc. | 23.12 Million USD | 48.467% |
| Alpha Teknova, Inc. | 128.58 Million USD | 90.731% |
| Bright Green Corporation | 17.4 Million USD | 31.517% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | 94.209% |
| Embecta Corp. | 1.21 Billion USD | 99.019% |
| PainReform Ltd. | 9.93 Million USD | -20.022% |
| Journey Medical Corporation | 76.84 Million USD | 84.491% |
| Procaps Group, S.A. | 460.18 Million USD | 97.41% |
| Theratechnologies Inc. | 77.76 Million USD | 84.675% |
| Harrow Health, Inc. | 311.75 Million USD | 96.177% |
| Sonoma Pharmaceuticals, Inc. | 14.89 Million USD | 19.975% |
| Biofrontera Inc. | 27.93 Million USD | 57.331% |
| DURECT Corporation | 45.18 Million USD | 73.626% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | 99.154% |
| Cronos Group Inc. | 1.13 Billion USD | 98.949% |
| OptiNose, Inc. | 107.72 Million USD | 88.937% |
| Ironwood Pharmaceuticals, Inc. | 471.07 Million USD | 97.47% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | 78.698% |
| RedHill Biopharma Ltd. | 23.04 Million USD | 48.288% |
| Organogenesis Holdings Inc. | 460.02 Million USD | 97.409% |
| Cumberland Pharmaceuticals Inc. | 81.77 Million USD | 85.426% |
| Radius Health, Inc. | 1.71 Billion USD | 99.305% |
| Universe Pharmaceuticals INC | 53.28 Million USD | 77.634% |
| ProPhase Labs, Inc. | 91.92 Million USD | 87.035% |
| Phibro Animal Health Corporation | 982.18 Million USD | 98.787% |
| Procaps Group S.A. | 460.18 Million USD | 97.41% |
| Alvotech | 950.09 Million USD | 98.746% |
| TherapeuticsMD, Inc. | 43.3 Million USD | 72.481% |
| Viatris Inc. | 47.68 Billion USD | 99.975% |
| Rockwell Medical, Inc. | 52.17 Million USD | 77.156% |
| Aytu BioPharma, Inc. | 118.09 Million USD | 89.908% |
| SIGA Technologies, Inc. | 254.83 Million USD | 95.323% |
| Tilray Brands, Inc. | 4.33 Billion USD | 99.725% |
| Lifecore Biomedical, Inc. | 273.7 Million USD | 95.646% |
| Shineco, Inc. | 84.17 Million USD | 85.842% |
| PetIQ, Inc. | 868.22 Million USD | 98.627% |
| Regencell Bioscience Holdings Limited | 8.43 Million USD | -41.241% |
| Incannex Healthcare Limited | 17.04 Million USD | 30.086% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | 99.633% |
| Alimera Sciences, Inc. | 153.52 Million USD | 92.237% |
| Silver Spike Investment Corp. | 88.57 Million USD | 86.545% |
| Assertio Holdings, Inc. | 286.41 Million USD | 95.839% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.95 Million USD | -100.247% |
| Petros Pharmaceuticals, Inc. | 33.79 Million USD | 64.735% |
| Clever Leaves Holdings Inc. | 31.24 Million USD | 61.853% |
| Cyclo Therapeutics, Inc. | 13.24 Million USD | 10.035% |
| Avadel Pharmaceuticals plc | 261.12 Million USD | 95.436% |
| Hempacco Co., Inc. | 18.04 Million USD | 33.946% |
| Talphera, Inc. | 20.39 Million USD | 41.563% |
| Alvotech | 950.09 Million USD | 98.746% |
| Eagle Pharmaceuticals, Inc. | 406.16 Million USD | 97.066% |
| Lantheus Holdings, Inc. | 1.65 Billion USD | 99.278% |
| Currenc Group, Inc. | 141.49 Million USD | 91.577% |
| Kamada Ltd. | 351.96 Million USD | 96.614% |
| Indivior PLC | 1.95 Billion USD | 99.389% |
| Evoke Pharma, Inc. | 7.06 Million USD | -68.609% |
| Flora Growth Corp. | 23.62 Million USD | 49.555% |
| Cyclo Therapeutics, Inc. | 13.24 Million USD | 10.035% |
| Evolus, Inc. | 188.99 Million USD | 93.694% |
| HUTCHMED (China) Limited | 1.27 Billion USD | 99.069% |
| Amphastar Pharmaceuticals, Inc. | 1.51 Billion USD | 99.212% |
| Akanda Corp. | 8.83 Million USD | -34.821% |